Joseph Buxbaum

Joseph Buxbaum serves as Professor of Psychiatry at Icahn School of Medicine at Mount Sinai and Director of the Seaver Autism Center for Research and Treatment. His academic appointments span multiple institutes including the Friedman Brain Institute, Genetics and Genomic Sciences, and the Mindich Child Health and Development Institute, reflecting his interdisciplinary research approach.

Dr. Buxbaum's research focuses on the genetic and molecular mechanisms underlying neurodevelopmental and psychiatric disorders. His laboratory investigates autism spectrum disorder through genetic mapping and functional characterization of susceptibility genes like SHANK2 and AGC1. In schizophrenia research, his team pioneered the oligodendrocyte dysfunction hypothesis based on microarray studies. For Alzheimer's disease, they examine amyloid precursor protein signaling pathways and calsenin function in amyloid processing.

His publication record demonstrates sustained productivity with 493 research outputs including over 400 articles. Recent work shows continued high output with 16 publications in 2023 and multiple 2024-2025 publications in high-impact journals. Analysis of his recent articles reveals strong emphasis on genomic approaches to autism, OCD, and dementia, with particular focus on rare variants, cross-disorder analyses, and functional validation.

Dr. Buxbaum's scientific impact is evidenced by his h-index of 132 and 85,766 citations. While specific awards aren't listed in the source material, his leadership of the Seaver Autism Center and participation in major genomic consortia indicate significant recognition in the field.

As director of the Laboratory of Molecular Neuropsychiatry, he mentors trainees in molecular analysis of neurological diseases using state-of-the-art techniques. His lab maintains active collaborations through the Trans-Ancestry OCD Genomics Initiative, Alzheimer's Disease Genetics Consortium, and international autism research networks. Current research leverages genomic sequencing, animal models, and stem cell technologies to advance understanding of neurodevelopmental disorders.